Home Technology Seminars

Technology Seminar (25 Apr 2008)

Print
Technology Seminar

Advanced disease marker discovery using
label free analysis of protein to protein
to protein/drug interaction & HCA cell imaging

By

Dr. Stehpen LOFAS
Chief Scientific Officer of Biacore R&D
GE Healthcare

on Friday, 25 April 2008 at 10:30 a.m.

Room L6-32, 6/F, Laboratory Block
Genome Research Centre
21 Sassoon Road, Pokfulam, Hong Kong
Abstract:

Biacore specializes in measuring protein-protein interaction and binding affinity. The technology is based on surface Plasmon resonance (SPR), an optical phenomenon that enables detection of unlabeled interactants in real time. The SPR-based biosensors can be used in determination of active concentration, screening and characterization in terms of both affinity and kinetics.
The presentation will describe recent progress of Biacore technology and highlight applications within drug discovery and development. This includes selection and detailed characterisation of the binding properties of biopharmaceuticals such as antibodies as well as new routes to find drug candidates based on small molecules. Here, Biacore is now used for compound fragment screening and with a throughput of 1400 fragments/day using only 10 ug of target protein. Information obtained includes the selectivity of binding and target site specificity that are important criteria in fragment selection. Not only affinities in the range from mM to pM can be measured but also the residence time (off-rate).

ALL ARE WELCOME
Co-organized with GE Healthcare

For enquiries, please call 2819-9848 or write to This e-mail address is being protected from spambots. You need JavaScript enabled to view it